We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
-8.66%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$419M
AUM Growth
-$20.7M
(-4.7%)
Cap. Flow
+$25.1M
Cap. Flow
% of AUM
5.99%
Top 10 Holdings %
Top 10 Hldgs %
47.79%
Holding
85
New
13
Increased
17
Reduced
18
Closed
2
Top Buys
| 1 |
AtriCure
ATRC
|
+$8.5M |
| 2 |
UroGen Pharma
URGN
|
+$6.67M |
| 3 |
Biohaven
BHVN
|
+$3.95M |
| 4 |
Alkermes
ALKS
|
+$2.96M |
| 5 |
SLRN
ACELYRIN
SLRN
|
+$2.3M |
Top Sells
| 1 |
Procept Biorobotics
PRCT
|
+$2.44M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$2.25M |
| 3 |
BioNTech
BNTX
|
+$1.57M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$1.56M |
| 5 |
Perspective Therapeutics
CATX
|
+$1.14M |
Sector Composition
| 1 | Healthcare | 85.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $41.3M | 9.86% |
445,005
+13,790
| +3% | +$1.24M |
|
2
Stereotaxis
STXS
$160M
| $24.9M | 5.95% |
13,680,554
| – | – |
|
|
MRUS
3
DELISTED
Merus
MRUS
| $24.2M | 5.79% |
409,445
+30,450
| +8% | +$1.47M |
|
4
Cytokinetics
CYTK
$11.2B
| $21.6M | 5.15% |
398,100
| – | – |
|
5
Revolution Medicines
RVMD
$39.3B
| $19.9M | 4.75% |
511,894
| – | – |
|
6
IDEAYA Biosciences
IDYA
$3.54B
| $14.8M | 3.54% |
422,213
-24,128
| -5% | -$956K |
|
|
7
AtriCure
ATRC
$1.75B
| $14.6M | 3.48% |
639,173
+368,144
| +136% | +$8.5M |
|
8
iShares Biotechnology ETF
IBB
$9.23B
| $14.1M | 3.36% |
102,500
| – | – |
|
9
Syndax Pharmaceuticals
SNDX
$2.08B
| $13.5M | 3.22% |
657,074
-2,500
| -0.4% | -$52.3K |
|
|
BPMC
10
DELISTED
Blueprint Medicines
BPMC
| $11.3M | 2.7% |
104,763
-2,000
| -2% | -$200K |
|
|
11
Ascendis Pharma A/S
ASND
$17.5B
| $11M | 2.64% |
80,972
-11,500
| -12% | -$1.56M |
|
12
Xenon Pharmaceuticals
XENE
$6.53B
| $10.7M | 2.55% |
273,739
| – | – |
|
13
Viking Therapeutics
VKTX
$4.44B
| $10M | 2.4% |
189,117
-5,000
| -3% | -$328K |
|
14
Neurocrine Biosciences
NBIX
$17.2B
| $9.86M | 2.36% |
71,615
| – | – |
|
|
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
| $9.51M | 2.27% |
806,973
| – | – |
|
|
DAWN
16
DELISTED
Day One Biopharmaceuticals
DAWN
| $9.18M | 2.19% |
666,463
| – | – |
|
17
Kura Oncology
KURA
$1B
| $8.72M | 2.08% |
423,500
+10,837
| +3% | +$223K |
|
|
18
Tandem Diabetes Care
TNDM
$1.06B
| $8.23M | 1.97% |
204,208
-54,000
| -21% | -$2.25M |
|
|
MORF
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $7.9M | 1.89% |
231,748
| – | – |
|
|
20
UroGen Pharma
URGN
$1.95B
| $7.87M | 1.88% |
+469,000
| New | +$6.67M |
|
|
21
Biohaven
BHVN
$2.24B
| $7.59M | 1.81% |
218,730
+100,000
| +84% | +$3.95M |
|
22
DexCom
DXCM
$28.1B
| $7.43M | 1.78% |
65,552
| – | – |
|
23
Axogen
AXGN
$2.04B
| $6.78M | 1.62% |
935,894
| – | – |
|
24
Edgewise Therapeutics
EWTX
$4.38B
| $5.23M | 1.25% |
290,197
-16,000
| -5% | -$279K |
|
25
Larimar Therapeutics
LRMR
$394M
| $4.64M | 1.11% |
639,974
-16,399
| -2% | -$126K |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML